Trial Profile
Stereotactic Intrastriatal Implantation of Spheramine in Advanced Parkinson's Disease Patients: A Pilot Study of Tolerability and Efficacy.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 09 Apr 2021
Price :
$35
*
At a glance
- Drugs Spheramine (Primary)
- Indications Parkinson's disease
- Focus Therapeutic Use
- Sponsors Bayer
- 21 May 2013 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 06 Jun 2012 Actual end date (May 2012) added as reported by ClinicalTrials.gov.
- 06 Jun 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.